TriSalus Life Sciences (NASDAQ: TLSI) reported Q2 EPS of ($0.16), $0.01 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $11.41 million versus the consensus estimate of $10.79 million.

For earnings history and earnings-related data on TriSalus Life Sciences (TLSI) click here.